Histone deacetylase inhibitors (HDIs) are valuable drugs in breast cancer where estrogen receptor α (ERα) can be silenced by epigenetic modifications. We report the effect of the clinically available HDI, valproic acid (VPA), on ERα expression and function in ER-negative breast cancer cells, MDA-MB-231. VPA induced ERα mRNA and protein, while did not modify ERβ. In VPA-treated cells, we also observed: (1) a correct transcriptional response to estradiol after transfection with the luciferase gene under the control of an estrogen-responsive minimal promoter (ERE-TKluc); (2) increased expression of the ER-related transcription factor FoxA1; (3) estradiol-induced up-regulation of several estrogen-regulated genes (e.g. pS2, progesterone receptor); (4) inhibitory effect of tamoxifen on cell growth. In conclusion, the HDI VPA, inducing ERα and FoxA1, confers to MDA-MB 231 cells an estrogen-sensitive “phenotype”, restoring their sensitivity to antiestrogen therapy.

Valproic acid restores ER-alpha and antiestrogen sensitivity to ER-alpha-negative breast cancer cells

DE BORTOLI, Michele;COMPAGNONE, Alessandra;BANDINO, Andrea;CATALANO, Maria Graziella;BOCCUZZI, Giuseppe
2010

Abstract

Histone deacetylase inhibitors (HDIs) are valuable drugs in breast cancer where estrogen receptor α (ERα) can be silenced by epigenetic modifications. We report the effect of the clinically available HDI, valproic acid (VPA), on ERα expression and function in ER-negative breast cancer cells, MDA-MB-231. VPA induced ERα mRNA and protein, while did not modify ERβ. In VPA-treated cells, we also observed: (1) a correct transcriptional response to estradiol after transfection with the luciferase gene under the control of an estrogen-responsive minimal promoter (ERE-TKluc); (2) increased expression of the ER-related transcription factor FoxA1; (3) estradiol-induced up-regulation of several estrogen-regulated genes (e.g. pS2, progesterone receptor); (4) inhibitory effect of tamoxifen on cell growth. In conclusion, the HDI VPA, inducing ERα and FoxA1, confers to MDA-MB 231 cells an estrogen-sensitive “phenotype”, restoring their sensitivity to antiestrogen therapy.
314
1
17
22
http://www.journals.elsevier.com/molecular-and-cellular-endocrinology/
Histone deacetylase inhibitors; Estrogen receptor; breast cancer; Epigenetics; tamoxifen
Fortunati N; Bertino S; Costantino L; De Bortoli M; Compagnone A; Bandino A; Catalano MG; Boccuzzi G
File in questo prodotto:
File Dimensione Formato  
Fortunati et al. 2010.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 820.55 kB
Formato Adobe PDF
820.55 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/61859
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 28
social impact